Pfizer has ended its trial of an SHP2 inhibitor that was being developed in cancer, the latest blow to the target after several other drugmakers have suffered setbacks.
The New York drugmaker ended the Phase 1 study of the drug, PF-07284892, “due to strategic reasons, not major safety concerns, futility, or requests from any regulatory authorities,” according to the trial registry update. The experimental medicine is still listed in Pfizer’s pipeline on its website.
A spokesperson for the company didn’t provide comment as of publication time.
Pfizer acquired the drug as part of its 2019 buyout of Array BioPharma. The $11.4 billion deal came with a portfolio of approved and in-development cancer treatments.
It’s not the first company to walk away from SHP2. Earlier this year, Roche ended a pact with Relay Therapeutics, and Bristol Myers Squibb also left a collaboration. AbbVie and Sanofi have ended SHP2…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
